secwatch.observer — SEC 8-K summary
======================================

Issuer:     SOLIGENIX, INC. (SNGX)
CIK:        0000812796
Form:       8-K
Filed at:   2026-06-12T20:05:59+00:00
Accession:  0001104659-26-073430
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Soligenix terminates HyBryte program after Phase 3 futility; receives Nasdaq bid price deficiency notice
--------------------------------------------------------------------------------

- Received Nasdaq notice for non-compliance with $1.00 minimum bid price; 180 days until Dec 7, 2026 to regain compliance.
- Board terminated HyBryte (synthetic hypericin) development program after DMC recommended halt for futility.
- Expected wind-down charges of approximately $70,000 from closing FLASH2 trial.
- Consulting CMO Richard Straube stepped down; duties transitioned to Medical Director Christopher Pullion.
- Company will evaluate strategic alternatives including M&A and advancing dusquetide (SGX945) for Behçet's Disease.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/812796/000110465926073430/0001104659-26-073430-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/812796/000110465926073430/sngx-20260610x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-073430

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer